Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of whats happening in your industry
Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist that commonly causes fatigue, especially during dose escalation, due to reduced caloric intake and gastrointestinal side effects
Weight loss results Metformin is not FDA-approved for weight management
A provider may review medical history, medications, weight-loss history, blood sugar markers, cardiovascular risk, gallbladder history, digestive symptoms, kidney or liver concerns, and nutrition status
Dual agonist of GLP-1 and glucagon receptors